Logo
x

Search

Subscribe Now

Option to License

AbbVie Signs an Exclusive Research and Option to License Agreement with Sosei Heptares Targeting Inflammatory and Autoimmune Diseases

AbbVie Signs an Exclusive Research and Option to License Agreement with Sosei Heptares Targeting Inflammatory and Autoimmune Disea...

  • June 26, 2020
Bayer Signs an Exclusive Option to License Agreement with Dare Biosciences to Commercialize Ovaprene in the US

Bayer Signs an Exclusive Option to License Agreement with Dare Biosciences to Commercialize Ovaprene in the US

  • January 14, 2020
Regeneron Signs a Research and Option to License Agreement with Vyriad for Oncolytic Virus-Based Therapies

Regeneron Signs a Research and Option to License Agreement with Vyriad for Oncolytic Virus-Based Therapies

  • November 6, 2019
Celgene Signs an Option to License Agreement with Immatics to Develop Novel Adoptive Cell Therapies Targeting Multiple Cancers

Celgene Signs an Option to License Agreement with Immatics to Develop Novel Adoptive Cell Therapies Targeting Multiple Cancers

  • August 29, 2019
GSK Exercises Its Option to License Ionis' Antisense Therapy for Chronic Hepatitis B Virus Infection

GSK Exercises Its Option to License Ionis' Antisense Therapy for Chronic Hepatitis B Virus Infection

  • August 27, 2019
Pfizer Exercised its Option to License AnTolRx's Immune Tolerance Therapy for Type 1 Diabetes (T1D)

Pfizer Exercised its Option to License AnTolRx's Immune Tolerance Therapy for Type 1 Diabetes (T1D)

  • March 6, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.